



UNITED STATE DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 08/532,384 09/22/95 ARTAVANTS-TSAKUNAS 5 7326-035

18M1/0327

EXAMINER EYLER, Y

PENNIE & EDMONDS 1155 AVENUE OF THE AMERICAS NEW YORK NY 10036-2711

ART UNIT PAPER NUMBER

DATE MAILED:

03/27/97

#7

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Application No. 08/532,384

Applicant(s)

Artavanis-Tsakonas

Examiner

Office Action Summary

Yvonne Eyler

Group Art Unit 1806



☐ Responsive to communication(s) filed on	
☐ This action is FINAL .	
☐ Since this application is in condition for allowance except for form in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D.	· •
A shortened statutory period for response to this action is set to expis longer, from the mailing date of this communication. Failure to resapplication to become abandoned. (35 U.S.C. § 133). Extensions of 37 CFR 1.136(a).	spond within the period for response will cause the
Disposition of Claims	
	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
Claim(s)	
Claim(s)	
Claim(s)	
X Claims 90-123	
Application Papers	•
☐ See the attached Notice of Draftsperson's Patent Drawing Rev	iew, PTO-948.
☐ The drawing(s) filed on is/are objected t	to by the Examiner.
☐ The proposed drawing correction, filed on	_ is _ approved _ disapproved.
☐ The specification is objected to by the Examiner.	
$\hfill\Box$ The oath or declaration is objected to by the Examiner.	
Priority under 35 U.S.C. § 119	
Acknowledgement is made of a claim for foreign priority under	35 U.S.C. § 119(a)-(d).
☐ All ☐ Some* ☐ None of the CERTIFIED copies of the	priority documents have been
received.	
received in Application No. (Series Code/Serial Number)	•
received in this national stage application from the Interr	
*Certified copies not received: Acknowledgement is made of a claim for domestic priority und	
	10.00 0.0.C. 3 110/e/.
Attachment(s) Notice of References Cited, PTO-892	
☐ Information Disclosure Statement(s), PTO-1449, Paper No(s).	•
☐ Interview Summary, PTO-413	
☐ Notice of Draftsperson's Patent Drawing Review, PTO-948	
☐ Notice of Informal Patent Application, PTO-152	
SEE OFFICE ACTION ON THE FO	OLLOWING PAGES

Art Unit: 1806

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 90, 92, 98-99, 101-106, and 109-119, drawn to a method of manipulating cell differentiation by promoting Notch function, classified in 424, subclass 130.1+.
- II. Claims 90, 91, 93-97, 100, 107, 108, and 120-123 drawn to a method of manipulating cell differentiation by antagonizing Notch function, classified in class 424, subclass 130.1+.
- 2. The inventions are distinct, each from the other because of the following reasons:

The inventions of Groups I and II are entirely different because the compositions of Group I which promote Notch function cannot be used in the methods of Group II to antagonize Notch functions and likewise, those of Group II which antagonize, cannot be used in Group I to promote. Claim 90 is common to both groups but will be examined in light of the group selected.

- 3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, and because these inventions are distinct for the reasons given above and the search required for Group I is not required for Group II, restriction for examination purposes as indicated is proper.
- 4 This application contains claims directed to the following patentably distinct species of the claimed invention:
 - A) The invention of Group I is further directed to the following species:

Art Unit: 1806

a) methods involving the toporythmic protein Delta (98, 103, 106, 109, 110, 113,

115, 118)

b) methods involving the toporythmic protein Serrate (98, 105, 106, 109, 111, 113,

116, 119)

c) methods involving Notch protein, fragments, or analogs (104, 106, 109,

112,113, 114, 117)

B) The invention of Group II is further directed to the following species:

a) methods involving antibodies or inhibitors of Notch (94,-96, 107, 108, 120-

123)

b) methods involving antibodies or inhibitors of Delta (94,95,120-123)

c) methods involving antibodies or inhibitors of Serrate (94,95, 120-123)

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Serial Number: 08/532384

Art Unit: 1806

Page 4

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

- 5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yvonne Eyler, Ph.D. whose telephone number is (703) 308-6564.

Yvonne Eyer, Ph.D. March 18, 1997

SUPERVISORY PATENT EXAMINER
GROUP 1800